Evidence map›Paper›PMID 40321230›Full record

ArticleClinical case reports2025

Comprehensive Whole-Course Management Strategy for Recurrent Renal Cell Carcinoma: Case Report and Literature Review.

PengNan Hu, Di Chen, Jun Yu, Hua Mi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

PengNan HuDepartment of Urology The First Affiliated Hospital of Guangxi Medical University Nanning China.ORCID https://orcid.org/0009-0000-5026-2293
Di ChenDepartment of Urology The First Affiliated Hospital of Guangxi Medical University Nanning China.
Jun YuDepartment of Urology The First Affiliated Hospital of Guangxi Medical University Nanning China.
Hua MiDepartment of Urology The First Affiliated Hospital of Guangxi Medical University Nanning China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma, a highly recurrent and metastatic malignancy. Drawing upon a decade-long expertise in managing recurrent cases, we advocate the adoption of Programmed Death-1 (PD-1) inhibitors in conjunction with Axitinib when monotherapy with Axitinib fails to restrain tumor metastasis, thereby empowering doctors with an efficacious treatment option.

Indexed as

comprehensive whole‐course managementimmunotherapymolecular targeted therapyNivolumabrecurrent renal cell carcinoma

Identifiers

PMID40321230
PMCPMC12045782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.